Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI‑HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmaco­economic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, multiple sclerosis, bipolar disease, breast cancer, hepatitis C and HIV infection and vaccines for infectious diseases. She has estimated the cost effectiveness of antiretroviral drugs, as well as drugs for treating Alzheimer’s disease, multiple sclerosis, fungal infections, herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, influenza vaccination, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Dr. Mauskopf has performed many strategic literature reviews that have been published in peer-reviewed journals, including reviews of cost of care for Alzheimer’s disease, cost of care for treatment-resistant depression, a review of the methods used to estimate the cost-effectiveness of vaccine programs using dynamic transmission models, cost-effectiveness of tiotropium for chronic obstructive pulmonary disease, and treatments for uterine fibroids. Dr. Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed simulation models of time spent in the operating and recovery rooms and of disease progression for HIV infection. Dr. Mauskopf has used multi-criteria decision analysis (MCDA) to estimate the likelihood of reimbursement for products with different attributes and to the impact of benefits and risks on drug prescribing decisions.